Awarded contract
Published
Oncotype DX Breast Cancer Testing
8 suppliers have saved this notice.
Looks like a fit? Save this tender and qualify it in Stotles
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Qualify tenders faster with AI summaries - see key details in the Stotles app
Never miss a tender again
Get alerts, AI summaries and tools to qualify faster
Explore similar pre-tenders, open or awarded contracts
Browse open tenders, recent contract awards and upcoming contract expiries that match similar CPV codes.
Royal United Hospitals Bath NHS Foundation Trust
422,400 GBP
Published 19 days ago
Betsi Cadwaladr University Health Board (BCUHB)
47,000 GBP
Published a month ago
Great Western Hospitals NHS Foundation Trust
237,528 GBP
Published a month ago
Salisbury NHS Foundation Trust
555,955 GBP
Published a month ago
HEALTHTRUST EUROPE LLP
42,000,000 GBP
Published a month ago
Northampton General Hospital NHS Trust
782.1 GBP
Published a month ago
Nottingham University Hospitals NHS Trust
25,000,000 GBP
Published a month ago
Awarded
Cellular Pathology
The Newcastle upon Tyne Hospitals NHS Foundation Trust
200,000 GBP
Published a month ago
Explore top buyers for public sector contracts
Discover open tenders, contract awards and upcoming contract expiries of thousands of public sector buyers below. Gain insights into their procurement activity, historical purchasing trends and more.
CPV Codes
Sign up to the Stotles Tender Tracker for free
Find even more contracts with advanced search capability and AI powered relevance scoring.